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Abstract 
The benefits of cardiac resynchronization therapy (CRT) in the health-related quality of 
life (HRQL) are largely demonstrated in selected patients with severe congestive heart 
failure (CHF). However, the differences between responders and non-responders, with 
regard to the effect of CRT in the various dimensions that constitute HRQL are still a 
matter of discussion. Objective: To evaluate the impact of CRT on the HRQL of patients 
with CHF refractory to optimal pharmacological therapy, within 6 months after CRT. 
Methods: 43 patients, submitted to successful implantation of CRT, were evaluated in 
hospital just before intervention and in the outpatient clinic within 6 months after CRT. 
HRQL was analyzed based on the Kansas City Cardiomyopathy Questionnaire (KCCQ). 
Patients were classified as super-responders (ejection fraction of left ventricle - LVEF - 
≥45% post-CRT), n=15, responders (sustained improvement in functional class and 
LVEF increased by 15%), n=19, and non-responders (no clinical or LVEF improvement), 
n=9. Results: In the group of super-responders, CRT was associated with an 
improvement in HRQL for the various fields and sums assessed (ρ<0.05); in responders, 
CRT has been associated with an improvement of HRQL in the various fields and sums, 
except in the self-efficacy dimension (ρ<0.05); in non-responders, CRT was not 
associated with improvement of HRQL. Conclusion: In a population with severe CHF 
undergoing CRT, the patients with clinical and echocardiographic positive response, 
obtained a favorable impact in all dimensions of HRQL, while the group without 
response to CRT showed no improvement. These data reinforces the importance of 
HRQL as a multidimensional tool for assessment of benefits in clinical practice. 
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Introduction 
Congestive heart failure (CHF) is a progressive syndrome with a high incidence and 
prevalence and poor prognosis: four-year mortality is around 50% (1). With ageing 
populations, increased survival following acute coronary syndrome and prevention of 
sudden arrhythmic death, many patients will develop dilated cardiomyopathy, which, 
because of its symptoms, patients’ awareness of their risk of dying, and the effects of 
therapy, together with frequent hospitalizations, has considerable impact on patients’ 
health-related quality of life (HRQL). 
The widespread use of HRQL instruments in research into CHF (both generic and 
specific) reflects the growing importance of this measure in clinical practice. Various 
studies have demonstrated its high prognostic value in predicting hospital readmission 
and mortality, and it is widely used as a predictor of outcomes of intervention in CHF 
patients (2-5). 
Assessment of patients’ state of health in clinical terms, or HRQL, is multifactorial, 
self-administered, subjective, and varies over time(6).  This subjectivity refers to the fact 
that HRQL can only be told by the one who is measured and not to the psychometrics 
proprieties of the instrument that must be valid and reliable.  
The benefits of cardiac resynchronization therapy (CRT) in the HRQL have been largely 
demonstrated in selected patients with severe CHF. However, the differences between 
responders and non-responders, with regard to the effect of CRT in the various 
dimensions of HRQL is still a matter of discussion. 
The aim of this study was to evaluate the impact of CRT on the HRQL of patients with 
CHF refractory to optimal pharmacological therapy regarding the type of therapeutic 
response, within 6 months after CRT. 
  
Methods 
 
Population 
43 patients, submitted to successful implantation of CRT were classified as super-
responders (left ventricle ejection fraction - LVEF - ≥45% post-CRT), n=15, responders 
(sustained improvement in functional class and LVEF increase by 15%), n=19 and non-
responders (no clinical or LVEF improvement), n=9 (Table 1). 
 
Table 1 – General Population Characteristics 
 
 
 
 
Type 
 
Superesponders 
(n=15) 
 
Responders  
(n=19) 
 
Nonresponders 
(n=9) 
     
Age M 65,1 63,2 62,8 
 DP 8,2 11,1 6,0 
     
Gender Male 46,7% 84,2% 77,8% 
 Female 53,3% 15,8% 22,2% 
     
LVEF pré-CRT M 29,5% 22,6% 23,9% 
 DP 4,5 6,2 6,5 
     
NYHA Class II   22,2% 
 Class III 100% 100% 66,7% 
 Class IV   11,1% 
 
 
 
Material 
HRQL was analyzed based on a specific measure for the CHF, the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) validated to Portugal (7). This instrument is 
composed of 23 itens divided into 5 domains: physical limitation, symptoms, quality of 
life, self-efficacy and social interference. The physical limitation domain measures the 
extent to which CHF symptoms have resullimited some of the patient’s physical activities 
over the previous two weeks. The symptom domain assesses the number of times that 
CHF symptoms such as fatigue, dyspnea or limb edema have occurred in the previous 
two weeks and whether there have been changes in symptoms during the same period. 
The self-efficacy domain measures the patient’s knowledge of how to avoid worsening of 
symptoms and of what to do if this occurs. The quality of life domain evaluates patients’ 
perception of their enjoyment of life and of their sense of discouragement due to their 
heart failure, while the social interference domain assesses how CHF affects the patient’s 
lifestyle. To facilitate interpretability, two summary scores were developed: the first, the 
functional status score, combines the physical limitation and symptom domains, and the 
second, the clinical summary score, combines the functional status score with the quality 
of life and social limitation domains. Subjects are requested to answer the 15 questions 
using Likert scales (8). 
 
Procedure 
Patients were evaluated at the hospital just before CRT implantation and in the outpatient 
clinic within 6 months after CRT. 
 
Results 
In the group of super-responders, CRT was associated with a significant improvement in 
HRQL for all fields and sums assessed (Table 2). 
 
Table 2 – Superesponders Health Related Quality of Life (n=15) 
KCCQ Domains Inicial 
Average 
(M) 
6 months 
Average 
(M) 
t-value 
(t) 
p-value 
(p) 
Physical Limitation 51,8 90,4 -6,5 0,000 
Symptoms 53,9 84,5 -4,4 0,001 
Self-efficacy 76,2 95,7 -2,4 0,035 
Quality of Life 38,7 85,1 -5,0 0,000 
Social Interference 55,8 85,7 -3,8 0,002 
Funcional Status 55,3 87,7 -6,0 0,000 
Clinical Summary 52,6 86,2 -6,1 0,000 
 
In responders, CRT was associated with an improvement of HRQL in various fields and 
sums, except in the self-efficacy domain (Table 3). 
 
Table 3 – Responders Health Related Quality of Life (n=19) 
KCCQ Domains Inicial 
Average 
(M) 
 6 months 
Average 
(M) 
t-value 
(t) 
p-value 
(p) 
Physical Limitation 63,1 89,1 -5,7 0,000 
Symptons 60,0 82,4 -3,6 0,002 
Self-efficacy 76,9 83,3 -0,7 NS 
Quality of Life 39,8 75,0 -5,3 0,000 
Social Interference 63,9 90,2 -3,9 0,001 
Funcional Status 62,6 86,6 -4,8 0,000 
Clinical Summary 59,2 84,9 -5,0 0,000 
N.S.- non significant 
 
 
In non-responders, CRT was not associated with improvement of HRQL (Table 4). 
 
Table 4 – Nonresponders Health Related Quality of Life (n=9) 
KCCQ Domains  Inicial 
Average 
(M) 
6 months 
Average 
(M) 
t-value 
(t) 
p-value 
(p) 
Physical Limitation 25,2 59,1 -1,9 NS 
Symptoms 46,5 63,6 -1,1 NS 
Self-efficacy 95,8 97,5 -0,8 NS 
Quality of Life 20,8 52,1 -1,6 NS 
Social Interference 37,5 63,8 -1,3 NS 
Funcional Status 38,0 63,8 -1,6 NS 
Clinical Summary 34,8 60,1 -1,5 NS 
N.S.- non significant 
 
 
 
Discussion 
The benefits of CRT in the HRQL have been largely demonstrated in selected patients 
with severe CHF, but the differences between responders and non-responders, with 
regard to the effect of CRT in the various dimensions of HRQL is still a matter of 
discussion. 
This study clarifies the relation between the clinical and the patient evaluation of the 
CRT. There was no difference between these evaluations, with the responders indicating 
a better HRQL and the nonresponders identifying no changes in life. 
About the responders, and because we use the KCCQ to measure HRQL in CHF, that is 
the only one  who measures the self-efficacy, we have seen that what differentiates the 
superesponders from the responders is the self-efficacy domain, being the knowledge of 
the clinical condition improved on the superesponders during the follow-up. 
 
 In conclusion, in a population with severe CHF undergoing CRT, the patients with 
positive clinical response and reverse remodeling, obtained a favorable impact in all 
dimensions of HRQL, while the group without response to CRT showed no 
improvement. These data reinforces the importance of HRQL as a multidimensional tool 
for assessment of benefits in clinical practice. 
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